EP
BCRX icon

Edgestream Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Edgestream Partners’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-30,675
Closed -$216K – 819
2023
Q2 		$216K Buy
+30,675
New +$246K 0.02% 685

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Edgestream Partners's BCRX Position: Q3 2023 in Review

Edgestream Partners sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2023, closing a stake of 30,675 shares — an estimated $216K sold.

Edgestream Partners first reported a position in BCRX in Q2 2023 and held it in 1 quarter. The position peaked at $216K in Q2 2023. 233 funds tracked by Wall St. Rank hold BCRX as of Q3 2023.

  • Edgestream Partners reported no remaining BioCryst Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Edgestream Partners sold 30,675 BioCryst Pharmaceuticals shares in Q3 2023, an estimated $216K.
  • Edgestream Partners first reported a position in BioCryst Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Edgestream Partners's BioCryst Pharmaceuticals position peaked at $216K in Q2 2023.
  • 233 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2023.

Based on Edgestream Partners's 13F filing for Q3 2023, filed 15 Nov 2023.